Bafna Pharma Standalone December 2021 Net Sales at Rs 20.46 crore, up 17.08% Y-o-Y

Bafna Pharmaceuticals standalone net profit rises 88.89% in the December 2021 quarter

Bafna Pharma in talks with multinational pharma firms for brand acquisition

Pharmaceuticals formulations major Bafna Pharmaceuticals Ltd was in advanced stage of discussion with some multi-national pharma companies for acquisitions of brands, a company official said.

In talks with MNCs pharma cos for acquisition of brands: Bafna pharma

​​The Earnings Before Interest Depreciation and Amortization (EBITDA) for the half year ending September 30, 2021 was at Rs 7.43 crore, as against Rs 4.28 crore registered in the same period of last financial year, the statement added.

In talks with multinational pharma cos for acquisition of brands: Bafna pharmaceuticals

The company in particular seeks ‘Rights Issue’ to meet its capital requirements.

Bafna Pharma board to consider various avenues for raising funds

Bafna Pharmaceuticals standalone net profit rises 15.47% in the June 2021 quarter

Onward Technologies Ltd, Sangam (India) Ltd, Bafna Pharmaceuticals Ltd and CHD Chemicals Ltd are among the other losers in the BSE’s ‘B’ group today, 22 July 2021.

Shakti Pumps (India) Ltd leads losers in ‘B’ group

Bafna Pharmaceuticals reports standalone net profit of Rs 2.64 crore in the March 2021 quarter

The packaging lines have received approval from the UK-MHRA (Medicines and Healthcare products Regulatory Agency) for the United Kingdom and the European Union (EU).

Bafna Pharma adds two fully automated packaging lines to existing capacity; Stock hits 5% upper circuit

Bafna Pharmaceuticals hit an upper circuit of 5% at Rs 135.15 after the UK drug regulator approved the company’s two newly added automated packaging lines.

Bafna Pharma spurts after UK MHRA approval for packaging lines

Hasn't fared well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is underpriced and is not in the overbought zone

Current price is less than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Bafna Pharmaceuticals Limited is a pharmaceutical company. The Company is engaged in the manufacture of drugs and medicines.